2016•Lung CancerOpen access

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

Antonio R. Lucena‐Araujo, Jason P. Moran, Paul A. VanderLaan, Dora Dias‐Santagata, Erik Folch, Adnan Majid, Michael S. Kent, Sidharta P. Gangadharan, Deepa Rangachari, Mark S. Huberman, Susumu Kobayashi, Daniel B. Costa

Open full text 19 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Crizotinib, Anaplastic lymphoma kinase, ALK inhibitor, Cancer research, Lung cancer, Medicine, Protein kinase domain, Kinase